Literature DB >> 7813502

Retrospective evaluation of a latex agglutination test for diagnosis of invasive aspergillosis in immunocompromised patients.

K Haynes1, T R Rogers.   

Abstract

A commercial latex agglutination (LA) test for the detection of circulating Aspergillus galactomannan was evaluated in sera obtained from 121 immunocompromised patients, including 19 with proven invasive pulmonary aspergillosis. Patient urine (the specimen of choice for detection of galactomannan) was not tested with the LA test as 34 of 81 specimens from controls gave false-positive results. The sensitivity (95%), specificity (90%) and negative predictive value (99%) of the LA test were similar to previously published results obtained with two EIAs. However, the positive predictive value was only 67% compared to > or = 95% obtained with the EIAs. In addition, the LA test was also of less value than the EIAs in predicting the onset of invasive pulmonary aspergillosis. It was the earliest indicator of infection in only 1 of 19 proven cases.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7813502     DOI: 10.1007/bf01973998

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  13 in total

1.  Aspergillus antigen latex test for diagnosis of invasive aspergillosis.

Authors:  D W Warnock; A B Foot; E M Johnson; S B Mitchell; J M Cornish; A Oakhill
Journal:  Lancet       Date:  1991-10-19       Impact factor: 79.321

2.  Galactomannan antigenemia and antigenuria in aspergillosis: studies in patients and experimentally infected rabbits.

Authors:  B Dupont; M Huber; S J Kim; J E Bennett
Journal:  J Infect Dis       Date:  1987-01       Impact factor: 5.226

3.  Value of antigen detection in predicting invasive pulmonary aspergillosis.

Authors:  T R Rogers; K A Haynes; R A Barnes
Journal:  Lancet       Date:  1990-11-17       Impact factor: 79.321

4.  Detection of circulating galactomannan by Pastorex Aspergillus in experimental invasive aspergillosis.

Authors:  J Van Cutsem; L Meulemans; F Van Gerven; D Stynen
Journal:  Mycoses       Date:  1990-02       Impact factor: 4.377

5.  Invasive aspergillosis. Absence of detectable antibody response.

Authors:  R C Young; J E Bennett
Journal:  Am Rev Respir Dis       Date:  1971-11

6.  Receptor-mediated clearance of Aspergillus galactomannan.

Authors:  J E Bennett; M M Friedman; B Dupont
Journal:  J Infect Dis       Date:  1987-05       Impact factor: 5.226

Review 7.  Recent progress and current problems in management of invasive fungal infections in patients with neoplastic diseases.

Authors:  T J Walsh; J W Lee; E Roilides; P A Pizzo
Journal:  Curr Opin Oncol       Date:  1992-08       Impact factor: 3.645

8.  Galactomannan antigenemia in invasive aspergillosis.

Authors:  E Reiss; P F Lehmann
Journal:  Infect Immun       Date:  1979-07       Impact factor: 3.441

9.  Detection of galactomannan antigenemia by enzyme immunoassay in experimental invasive aspergillosis.

Authors:  L de Repentigny; M Boushira; L Ste-Marie; G Bosisio
Journal:  J Clin Microbiol       Date:  1987-05       Impact factor: 5.948

10.  Detection of circulating Aspergillus fumigatus antigen in bone marrow transplant patients.

Authors:  T M Johnson; V P Kurup; A Resnick; R C Ash; J N Fink; J Kalbfleisch
Journal:  J Lab Clin Med       Date:  1989-12
View more
  12 in total

1.  Aspergillus antigen testing in bone marrow transplant recipients.

Authors:  E C Williamson; D A Oliver; E M Johnson; A B Foot; D I Marks; D W Warnock
Journal:  J Clin Pathol       Date:  2000-05       Impact factor: 3.411

2.  Clinical evaluation and reproducibility of the Pastorex Aspergillus antigen latex agglutination test for diagnosing invasive aspergillosis.

Authors:  P E Verweij; A J Rijs; B E De Pauw; A M Horrevorts; J A Hoogkamp-Korstanje; J F Meis
Journal:  J Clin Pathol       Date:  1995-05       Impact factor: 3.411

3.  Comparison of antigen detection and PCR assay using bronchoalveolar lavage fluid for diagnosing invasive pulmonary aspergillosis in patients receiving treatment for hematological malignancies.

Authors:  P E Verweij; J P Latgé; A J Rijs; W J Melchers; B E De Pauw; J A Hoogkamp-Korstanje; J F Meis
Journal:  J Clin Microbiol       Date:  1995-12       Impact factor: 5.948

4.  Sandwich enzyme-linked immunosorbent assay compared with Pastorex latex agglutination test for diagnosing invasive aspergillosis in immunocompromised patients.

Authors:  P E Verweij; D Stynen; A J Rijs; B E de Pauw; J A Hoogkamp-Korstanje; J F Meis
Journal:  J Clin Microbiol       Date:  1995-07       Impact factor: 5.948

Review 5.  Aspergillus fumigatus and aspergillosis.

Authors:  J P Latgé
Journal:  Clin Microbiol Rev       Date:  1999-04       Impact factor: 26.132

6.  Comparison of commercial latex agglutination and sandwich enzyme immunoassays with a competitive binding inhibition enzyme immunoassay for detection of antigenemia and antigenuria in a rabbit model of invasive aspergillosis.

Authors:  S F Hurst; G H Reyes; D W McLaughlin; E Reiss; C J Morrison
Journal:  Clin Diagn Lab Immunol       Date:  2000-05

7.  Postmortem analysis of invasive aspergillosis in a tertiary care hospital.

Authors:  M Vogeser; A Haas; D Aust; G Ruckdeschel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-01       Impact factor: 3.267

8.  Specific detection of Aspergillus species in blood and bronchoalveolar lavage samples of immunocompromised patients by two-step PCR.

Authors:  H Skladny; D Buchheidt; C Baust; F Krieg-Schneider; W Seifarth; C Leib-Mösch; R Hehlmann
Journal:  J Clin Microbiol       Date:  1999-12       Impact factor: 5.948

9.  A polymerase chain reaction enzyme immunoassay for diagnosing infection caused by Aspergillus fumigatus.

Authors:  N Golbang; J P Burnie; R C Matthews
Journal:  J Clin Pathol       Date:  1999-06       Impact factor: 3.411

Review 10.  Current status of nonculture methods for diagnosis of invasive fungal infections.

Authors:  Siew Fah Yeo; Brian Wong
Journal:  Clin Microbiol Rev       Date:  2002-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.